Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Clinical trial NCT05800756 · UNKNOWN
Trial details
- NCT number
- NCT05800756
- Sponsor
- Yantai Yuhuangding Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-04
- Primary completion
- 2024-05-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.